OMERS ADMINISTRATION Corp Makes New Investment in Gossamer Bio, Inc. $GOSS

Key Points

• OMERS ADMINISTRATION Corp acquired a new stake in Gossamer Bio, purchasing 351,600 shares valued at approximately $387,000, representing about 0.15% of the company.
• Gossamer Bio recently reported a quarterly loss of ($0.17) earnings per share, slightly beating the consensus estimate of ($0.18), with a revenue of $11.49 million for the quarter.
• Several institutional investors have increased their positions in Gossamer Bio, with Octagon Capital Advisors LP raising its holdings by 99.7%, now owning 18.35 million shares.

OMERS ADMINISTRATION Corp purchased a new stake in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 351,600 shares of the company's stock, valued at approximately $387,000. OMERS ADMINISTRATION Corp owned about 0.15% of Gossamer Bio at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Octagon Capital Advisors LP grew its position in shares of Gossamer Bio by 99.7% in the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company's stock valued at $16,599,000 after buying an additional 9,162,117 shares during the last quarter. Millennium Management LLC grew its position in shares of Gossamer Bio by 14.6% in the 4th quarter. Millennium Management LLC now owns 3,586,067 shares of the company's stock valued at $3,244,000 after buying an additional 457,179 shares during the last quarter. Two Sigma Advisers LP grew its position in shares of Gossamer Bio by 44.7% in the 4th quarter. Two Sigma Advisers LP now owns 1,157,500 shares of the company's stock valued at $1,047,000 after buying an additional 357,500 shares during the last quarter. Two Sigma Investments LP grew its position in shares of Gossamer Bio by 41.3% in the 4th quarter. Two Sigma Investments LP now owns 891,279 shares of the company's stock valued at $806,000 after buying an additional 260,318 shares during the last quarter. Finally, Mackenzie Financial Corp grew its position in shares of Gossamer Bio by 17.6% in the 1st quarter. Mackenzie Financial Corp now owns 352,473 shares of the company's stock valued at $388,000 after buying an additional 52,658 shares during the last quarter. Institutional investors own 81.23% of the company's stock.

Gossamer Bio Stock Up 3.6%

GOSS traded up $0.10 during midday trading on Tuesday, reaching $2.76. 932,163 shares of the company were exchanged, compared to its average volume of 2,108,061. The company has a debt-to-equity ratio of 6.70, a quick ratio of 4.40 and a current ratio of 4.40. The company's fifty day moving average price is $1.93 and its 200 day moving average price is $1.41. The company has a market cap of $626.43 million, a price-to-earnings ratio of -4.41 and a beta of 1.95. Gossamer Bio, Inc. has a one year low of $0.66 and a one year high of $3.00.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.01. The firm had revenue of $11.49 million during the quarter, compared to analyst estimates of $4.12 million. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 344.81%. As a group, analysts expect that Gossamer Bio, Inc. will post -0.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Scotiabank assumed coverage on Gossamer Bio in a research report on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 price target on the stock. Wedbush upped their price target on Gossamer Bio from $4.00 to $5.00 and gave the company an "outperform" rating in a research report on Wednesday, August 6th. Wall Street Zen downgraded Gossamer Bio from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Finally, The Goldman Sachs Group boosted their price objective on Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Friday, May 16th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $8.50.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.